Skip to main content
DongKookPharmaceuticalCo.,Ltd. logo

DongKookPharmaceuticalCo.,Ltd. — Investor Relations & Filings

Ticker · 086450 ISIN · KR7086450004 KO Manufacturing
Open in API
Filings indexed 159 across all filing types
Latest filing 2023-03-13 AGM Information
Country KR South Korea
Listing KO 086450

About DongKookPharmaceuticalCo.,Ltd.

https://www.dkpharm.co.kr/en/

DongKook Pharmaceutical Co., Ltd. is a pharmaceutical company engaged in the research, development, manufacturing, and distribution of medical products. Established in 1968, the company focuses on improving human health and quality of life. Its product portfolio includes prescription and non-prescription drugs, with key therapeutic areas in anesthetics, contrast media, anti-cancer agents, antibiotics, and oral healthcare treatments. The company operates its own Active Pharmaceutical Ingredient (API) synthesis facilities and invests in research and development to create innovative therapeutic solutions. It provides both finished products and raw materials to domestic and international markets.

Recent filings

Filing Released Lang Actions
[기재정정]주주총회소집공고
AGM Information Classification · 98% confidence The document is a 'Notice of Convocation of the Annual General Meeting' (주주총회소집공고) for Dongkook Pharmaceutical. It contains the meeting agenda, voting procedures, director information, and financial statements for the 55th fiscal year. This document is a formal proxy statement and meeting notice provided to shareholders to inform them of the upcoming AGM and request their participation/votes. In the context of the provided categories, this fits the 'Proxy Solicitation & Information Statement' (PSI) classification.
2023-03-13 Korean
주주총회소집공고
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a 'Notice of General Meeting of Shareholders' (주주총회소집공고) for Dongkook Pharmaceutical Co., Ltd. It contains the agenda for the 55th Annual General Meeting, including reports on financial statements, director appointments, and dividend proposals. In the context of financial filings, this document is a Proxy Solicitation & Information Statement (PSI) as it provides shareholders with the necessary information to vote on matters at the upcoming meeting.
2023-03-09 Korean
현금ㆍ현물배당결정
Notice of Dividend Amount Classification · 100% confidence The document is a formal announcement from Dongkook Pharmaceutical regarding the decision to pay cash dividends. It specifies the dividend amount per share, the dividend record date, the expected payment date, and the approval process via the general meeting of shareholders. This aligns perfectly with the definition of a 'Notice of Dividend Amount' (DIV).
2023-02-09 Korean
주주총회소집결의
AGM Information Classification · 98% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집결의) issued by Dongkook Pharmaceutical. It outlines the date, location, and agenda items (such as approval of financial statements, election of directors, and remuneration limits) for the upcoming 55th Annual General Meeting. This document serves as a proxy solicitation and notice of meeting, which falls under the Proxy Solicitation & Information Statement category.
2023-02-09 Korean
주주총회집중일개최사유신고
AGM Information Classification · 98% confidence The document is a formal notification filed by Dongkook Pharmaceutical regarding the scheduling of their Annual General Meeting (AGM) on a 'concentrated date' (a date when many companies hold their AGMs). It explains the internal reasons for this scheduling conflict. Since this is a regulatory notification regarding meeting logistics rather than the AGM presentation materials themselves, and it does not fit into specific categories like proxy solicitation or voting results, it falls under the general regulatory filing category.
2023-02-09 Korean
주주명부폐쇄기간또는기준일설정
Notice of Dividend Amount Classification · 95% confidence The document is a short regulatory announcement from Dongkuk Pharmaceutical regarding the setting of a record date for the purpose of determining shareholder voting rights for an upcoming Annual General Meeting. It does not contain the full report or proxy materials themselves, but rather serves as a formal notice of a corporate action related to shareholder meetings. Given the nature of the announcement, it fits best under the general regulatory filing category.
2022-12-13 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.